Janssen Alzheimer Immunotherapy Research & Development, L.L.C.

About Janssen Alzheimer Immunotherapy Research & Development, L.L.C.

Janssen Alzheimer Immunotherapy (Janssen AI) is dedicated to developing treatments for Alzheimer's disease, a degenerative brain disease that has no cure.

According to the 2010 World Alzheimer's Report, an estimated 35.6 are living with dementia and this number is expected to nearly double every 20 years. Despite this growth and the far reaching human
 – more... and financial impact of Alzheimer's disease, there are no currently available treatments that fundamentally change the course of this fatal disease. At Janssen AI, our commitment is to find those medicines.

Working with medical professionals, patients, caregivers and the broader Alzheimer's disease community, our commitment is to deliver innovative therapies and support to people with Alzheimer's disease and their caregivers.

Janssen Alzheimer Immunotherapy is a Johnson & Johnson affiliate. The compounds in our Alzheimer's Immunotherapy Program (AIP) were acquired from Elan Pharmaceuticals and are being developed in collaboration with Pfizer. The company has approximately 200 employees located primarily in South San Francisco, California, and Dublin, Ireland where the company is headquartered.

Janssen Alzheimer Immunotherapy is named in honor of Dr. Paul Janssen, the Belgian scientist whose vision and intellect was the cornerstone of Johnson & Johnson's ability to become a global leader in neuroscience. – lessMore from ZoomInfo »

Janssen Alzheimer Immunotherapy Research & Development, L.L.C. Employer Reviews

Working at Janssen Alzheimer Immunotherapy Research & Development, L.L.C.